Genedrive (GDR.L) Stock Analysis & Winston Score
Genedrive Plc is a small British medical diagnostics company that makes portable, rapid genetic testing devices. Its main product is a point-of-care molecular testing platform that can detect infectious diseases and genetic variants quickly, without needing a large laboratory. The company has focused on tests for conditions like hepatitis C and pharmacogenetic testing — for example, helping doctors check whether a patient's genes affect how they respond to certain antibiotics. Genedrive earns money by selling its testing hardware and the single-use cartridges that run each test, a model similar to a printer and ink. It operates primarily in the UK and has pursued partnerships with the National Health Service and international health organizations to expand reach. The company is very small, currently loss-making, and burns through cash, which is its most immediate risk. Future growth depends on winning larger NHS contracts and expanding into new disease areas, but limited scale and funding constraints make that path uncertain.
Winston Score: 27/100 — Below Average
Below-average fundamentals — multiple weak pillars.
- Quality: Mixed (10/30)
- Growth: Mixed (6/20)
- Cash Flow: Weak (0/10)
- Stability: Data not available (0/10)
- Valuation: Data not available (0/10)
- Ownership: Good (10/15)
Key Facts
Price: 1.03 GBp
Market Cap: 6M GBp
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Exchange: London Stock Exchange
